VRUS is not the first company to test an HCV drug with ribavirin without interferon. Idera has been doing it since 2009 (http://clinicaltrials.gov/ct2/show/NCT00990938 ), and Coley Pharmaceuticals (acquired by PFE) did it several years ago.
VRUS is the first company to test a second-generation nuke in this manner, however.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.